ClinicalTrials.gg
RecruitingNCT07005505Updated Oct 28, 2026

Automatic Tube Compensation vs. Pressure Support Ventilation During Spontaneous Breathing Trials in Adults

An interventional study of Pressure Support Ventilation (PSV) and Automatic tube compensation (ATC) in Spontaneous Breathing Trial in ICU, sponsored by Rush University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Rush University Medical Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 28, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

For patients requiring mechanical ventilation, spontaneous breathing trials (SBTs) are conducted to determine if it is safe to remove the breathing tube. There are multiple methods for conducting SBTs. The purpose of this study is to compare the effects of 2 methods, pressure support ventilation (PSV) versus automatic tube compensation (ATC), on successful extubation for critically ill adult patients who received mechanical ventilation for over 24 hours.

Read the detailed description

The delivery of pressure support through the ventilator can be fixed using the pressure support ventilation (PSV) mode or variable using the automatic tube compensation (ATC) mode. Similar to PSV, ATC provides pressure support but dynamically adjusts it to compensate the resistive work of breathing and the mechanical load on respiratory muscles imposed by an artificial airway, such as an endotracheal or tracheostomy tube. Although both ATC and PSV are licensed and used in clinical practice, the optimal method to deliver pressure support during a spontaneous breathing trial (SBT) remains unknown. At Rush University Medical Center, ATC has been used for SBTs for over a decade. However, given the growing popularity of PSV, the SBT protocol was updated and now approves the use of PSV and ATC as standard care for SBT without making a recommendation for a preferred mode. The choice between PSV and ATC during SBT is left to the discretion of the clinician, reflecting the ongoing equipoise in the conduct of the SBT. As patients will be exposed to the potential benefits and risks of PSV or ATC under this change in clinical practice, the investigators are conducting a cluster-randomized cluster-crossover trial to compare the mode's effect on successful extubation.

02

Conditions studied

  • Spontaneous Breathing Trial in ICU

Keywords

  • Ventilator liberation
  • Spontaneous breathing trial
03

In context

Lead sponsor

Rush University Medical Center is the lead sponsor of 397 studies on the registry; 60 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to intensive care unit (ICU)
  • Age 18 years or older
  • Requiring invasive mechanical ventilation for at least 24 hours
  • Pass spontaneous breathing trial screen criteria

Exclusion criteria

Exclusion Criteria:

  • Do not intubate (DNI) order
  • Presence of tracheostomy
  • Pregnancy
  • Known prisoner
  • Immediate need for extubation, self-extubation, or unplanned extubation that precludes safe performance of study procedures
  • Enrolled in another clinical trial that impacts ventilator weaning or liberation
  • Receive veno-venous extracorporeal membrane oxygenation (VV-ECMO)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    Adult Intensive Care Unit (AICU)

    Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)

  • Experimental
    Medical Intensive Care Unit (MICU)

    Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)

  • Experimental
    Cardiosciences Intensive Care Unit (CSICU)

    Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)

  • Experimental
    Neuroscience Intensive Care Unit (NSICU)

    Other: Pressure Support Ventilation (PSV) · Other: Automatic tube compensation (ATC)

Interventions

  • OtherPressure Support Ventilation (PSV)

    Spontaneous breathing trials will be conducted using the mode pressure support ventilation (PSV) with settings of a pressure support of 5 cmH2O and positive end expiratory pressure (PEEP) 5 cmH2O.

  • OtherAutomatic tube compensation (ATC)

    Spontaneous breathing trials will be conducted using the mode automatic tube compensation (ATC) with settings of 100% tube compensation and a positive end expiratory pressure (PEEP) of 5 cmH2O.

06

What researchers measure

Primary outcomes

  1. Reintubation, continued invasive mechanical ventilation, or death

    Time frame: 48 hours after receiving the first SBT

Secondary outcomes

  1. Time to successful extubation

    The duration (in hours) from the first spontaneous breathing trial (SBT) initiation to extubation without reintubation within 48 hours

    Time frame: From the start of the first spontaneous breathing trial (SBT) to the first successful extubation (without reintubation within 48 hours) or death from any cause, whichever occurred first, assessed up to 30 days.

Other outcomes

  1. Ventilator-free days

    The number of days without mechanical ventilation after enrollment and up to 28 days

    Time frame: From study enrollment to 28 days after enrollment

  2. ICU free days, censored at day 28

    The number of days out of the ICU after enrollment and up to 28 days

    Time frame: From study enrollment to 28 days after enrollment

  3. Hospital free days

    The number of days out of the hospital after enrollment and up to 28 days

    Time frame: From study enrollment to 28 days after enrollment

  4. Spontaneous breathing trial (SBT) results

    SBT results (pass or fail) for the first 3 attempts if conducted

    Time frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first

  5. Reintubation

    Time frame: Within 48 hours after extubation

  6. Reintubation

    Time frame: Within 7 days after extubation

  7. Use of noninvasive respiratory support

    Use of noninvasive ventilation, continuous positive airway pressure (CPAP), and high flow nasal cannula (HFNC) and its duration

    Time frame: Within 48 hours of extubation

  8. Total duration of mechanical ventilation

    Time frame: From the date of intubation to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days

  9. Intensive care unit (ICU) length of stay (LOS)

    Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.

  10. Hospital length of stay (LOS)

    Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.

  11. Mortality

    Time frame: At ICU discharge, censored at 28 days

  12. Clinician adherence to initially assigned spontaneous breathing trial (SBT) mode

    Time frame: Up to 30 days

  13. Safety Events During SBT

    Occurrence of pneumothroax, unintentional extubation, or unstable cardiac rhythm during the SBT

    Time frame: From study enrollment to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Latronico N, Rasulo FA, Eikermann M, Piva S. Illness Weakness, Polyneuropathy and Myopathy: Diagnosis, treatment, and long-term outcomes. Crit Care. 2023 Nov 13;27(1):439. doi: 10.1186/s13054-023-04676-3. PubMed 37957759 ↗
  • Hoshino T, Yoshida T. Spontaneous breathing-induced lung injury in mechanically ventilated patients. Curr Opin Crit Care. 2025 Feb 1;31(1):5-11. doi: 10.1097/MCC.0000000000001231. Epub 2024 Nov 8. PubMed 39526662 ↗
  • Li W, Cai J, Ding L, Chen Y, Wang X, Xu H. Incidence and risk factors of ventilator-associated pneumonia in the intensive care unit: a systematic review and meta-analysis. J Thorac Dis. 2024 Sep 30;16(9):5518-5528. doi: 10.21037/jtd-24-150. Epub 2024 Sep 14. PubMed 39444919 ↗
  • Guerin C, Terzi N, Mezidi M, Baboi L, Chebib N, Yonis H, Argaud L, Heunks L, Louis B. Low-pressure support vs automatic tube compensation during spontaneous breathing trial for weaning. Ann Intensive Care. 2019 Dec 13;9(1):137. doi: 10.1186/s13613-019-0611-y. PubMed 31836913 ↗
  • El-Shahat, H., Salama, S., Wafy, S. et al. Automatic tube compensation versus pressure support ventilation as a weaning mode: does it make a difference?. Egypt J Bronchol 9, 253-260 (2015). https://doi.org/10.4103/1687-8426.165905
  • Haberthur C, Mols G, Elsasser S, Bingisser R, Stocker R, Guttmann J. Extubation after breathing trials with automatic tube compensation, T-tube, or pressure support ventilation. Acta Anaesthesiol Scand. 2002 Sep;46(8):973-9. doi: 10.1034/j.1399-6576.2002.460808.x. PubMed 12190798 ↗
  • Cohen J, Shapiro M, Grozovski E, Fox B, Lev S, Singer P. Prediction of extubation outcome: a randomised, controlled trial with automatic tube compensation vs. pressure support ventilation. Crit Care. 2009;13(1):R21. doi: 10.1186/cc7724. Epub 2009 Feb 23. PubMed 19236688 ↗
  • Cardinal-Fernandez P, Bougnaud J, Cour M, Argaud L, Poole D, Guerin C. Automatic Tube Compensation During Spontaneous Breathing Trials. Respir Care. 2022 Oct;67(10):1335-1342. doi: 10.4187/respcare.09920. Epub 2022 Jun 21. PubMed 36137582 ↗
  • Guttmann J, Haberthur C, Mols G, Lichtwarck-Aschoff M. Automatic tube compensation (ATC). Minerva Anestesiol. 2002 May;68(5):369-77. PubMed 12029248 ↗
  • Burns KEA, Wong J, Rizvi L, Lafreniere-Roula M, Thorpe K, Devlin JW, Cook DJ, Seely A, Dodek PM, Tanios M, Piraino T, Gouskos A, Kiedrowski KC, Kay P, Mitchell S, Merner GW, Mayette M, D'Aragon F, Lamontagne F, Rochwerg B, Turgeon A, Sia YT, Charbonney E, Aslanian P, Criner GJ, Hyzy RC, Beitler JR, Kassis EB, Kutsogiannis DJ, Meade MO, Liebler J, Iyer-Kumar S, Tsang J, Cirone R, Shanholtz C, Hill NS; Canadian Critical Care Trials Group. Frequency of Screening and Spontaneous Breathing Trial Techniques: A Randomized Clinical Trial. JAMA. 2024 Dec 3;332(21):1808-1821. doi: 10.1001/jama.2024.20631. PubMed 39382222 ↗
  • Burns KEA, Sadeghirad B, Ghadimi M, Khan J, Phoophiboon V, Trivedi V, Gomez Builes C, Giammarioli B, Lewis K, Chaudhuri D, Desai K, Friedrich JO. Comparative effectiveness of alternative spontaneous breathing trial techniques: a systematic review and network meta-analysis of randomized trials. Crit Care. 2024 Jun 8;28(1):194. doi: 10.1186/s13054-024-04958-4. PubMed 38849936 ↗
  • Burns KEA, Khan J, Phoophiboon V, Trivedi V, Gomez-Builes JC, Giammarioli B, Lewis K, Chaudhuri D, Desai K, Friedrich JO. Spontaneous Breathing Trial Techniques for Extubating Adults and Children Who Are Critically Ill: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2356794. doi: 10.1001/jamanetworkopen.2023.56794. PubMed 38393729 ↗
  • Roberts KJ, Goodfellow LT, Battey-Muse CM, Hoerr CA, Carreon ML, Sorg ME, Glogowski J, Girard TD, MacIntyre NR, Hess DR. AARC Clinical Practice Guideline: Spontaneous Breathing Trials for Liberation From Adult Mechanical Ventilation. Respir Care. 2024 Jun 28;69(7):891-901. doi: 10.4187/respcare.11735. PubMed 38443142 ↗
  • Mart MF, Brummel NE, Ely EW. The ABCDEF Bundle for the Respiratory Therapist. Respir Care. 2019 Dec;64(12):1561-1573. doi: 10.4187/respcare.07235. Epub 2019 Nov 5. PubMed 31690615 ↗
  • Boles JM, Bion J, Connors A, Herridge M, Marsh B, Melot C, Pearl R, Silverman H, Stanchina M, Vieillard-Baron A, Welte T. Weaning from mechanical ventilation. Eur Respir J. 2007 May;29(5):1033-56. doi: 10.1183/09031936.00010206. PubMed 17470624 ↗
  • Roberts KJ. 2022 Year in Review: Ventilator Liberation. Respir Care. 2023 Nov 25;68(12):1728-1735. doi: 10.4187/respcare.11114. PubMed 37402584 ↗
  • Trudzinski FC, Neetz B, Bornitz F, Muller M, Weis A, Kronsteiner D, Herth FJF, Sturm N, Gassmann V, Frerk T, Neurohr C, Ghiani A, Joves B, Schneider A, Szecsenyi J, von Schumann S, Meis J. Risk Factors for Prolonged Mechanical Ventilation and Weaning Failure: A Systematic Review. Respiration. 2022;101(10):959-969. doi: 10.1159/000525604. Epub 2022 Aug 17. PubMed 35977525 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
Jun 5, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion added, 1 removed
What changed in the criteria
Exclusion criteria
  • RemovedClinical decision made not to proceed with extubation regardless of spontaneous breathing trial (SBT) results
  • AddedReceive veno-venous extracorporeal membrane oxygenation (VV-ECMO)
Oct 28, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedReintubation, continued invasive mechanical ventilation, or deathTime frame: 48 hours after receiving the first SBT
  • RemovedReintubationTime frame: Within 48 hours of extubation
  • RemovedDeathTime frame: Within 48 hours of extubation
Oct 28, 2026
Secondary outcomes
13 added, 12 removed, 1 description edited
What changed in the outcomes
  • RemovedSpontaneous breathing trial (SBT) resultsTime frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first.
  • RemovedReintubationTime frame: within 24 hours of extubation
  • RemovedReintubationTime frame: Within 72 hours of extubation
  • RemovedReintubationTime frame: Within 7 days of extubation
  • RemovedUse of noninvasive respiratory supportTime frame: Within 48 hours of extubation
  • RemovedTotal duration of mechanical ventilationTime frame: From the date of intubation to the date of extubation without reintubation within 28 hours or date of death from any cause, whichever occurs first, assessed up to 30 days.
  • RemovedIntensive care unit (ICU) length of stay (LOS)Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.
  • RemovedHospital length of stay (LOS)Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
  • RemovedMortalityTime frame: At intensive care unit (ICU) discharge
  • RemovedMortalityTime frame: Up to 30 days
  • RemovedClinician adherence to initially assigned spontaneous breathing trial (SBT) modeTime frame: Up to 30 days
  • RemovedVentilator associated complicationsTime frame: From the date of intubation to the date of extubation without reintubation in 48 hours or death from any cause, whichever occurs first, assessed up to 30 days.
  • DescriptionTime to successful extubation: how it is measured was reworded
  • Addedother outcomeVentilator-free daysTime frame: From study enrollment to 28 days after enrollment
  • Addedother outcomeICU free days, censored at day 28Time frame: From study enrollment to 28 days after enrollment
  • Addedother outcomeHospital free daysTime frame: From study enrollment to 28 days after enrollment
  • Addedother outcomeSpontaneous breathing trial (SBT) resultsTime frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first
  • Addedother outcomeReintubationTime frame: Within 48 hours after extubation
  • Addedother outcomeReintubationTime frame: Within 7 days after extubation
  • Addedother outcomeUse of noninvasive respiratory supportTime frame: Within 48 hours of extubation
  • Addedother outcomeTotal duration of mechanical ventilationTime frame: From the date of intubation to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
  • Addedother outcomeIntensive care unit (ICU) length of stay (LOS)Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.
  • Addedother outcomeHospital length of stay (LOS)Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
  • Addedother outcomeMortalityTime frame: At ICU discharge, censored at 28 days
  • Addedother outcomeClinician adherence to initially assigned spontaneous breathing trial (SBT) modeTime frame: Up to 30 days
  • Addedother outcomeSafety Events During SBTTime frame: From study enrollment to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Eligibility 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedClinical decision made not to proceed with extubation regardless of spontaneous breathing trial (SBT) results
    • AddedReceive veno-venous extracorporeal membrane oxygenation (VV-ECMO)
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedReintubation, continued invasive mechanical ventilation, or deathTime frame: 48 hours after receiving the first SBT
    • RemovedReintubationTime frame: Within 48 hours of extubation
    • RemovedDeathTime frame: Within 48 hours of extubation
    Secondary outcomes 13 added, 12 removed, 1 description edited
    What changed in the outcomes
    • RemovedSpontaneous breathing trial (SBT) resultsTime frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first.
    • RemovedReintubationTime frame: within 24 hours of extubation
    • RemovedReintubationTime frame: Within 72 hours of extubation
    • RemovedReintubationTime frame: Within 7 days of extubation
    • RemovedUse of noninvasive respiratory supportTime frame: Within 48 hours of extubation
    • RemovedTotal duration of mechanical ventilationTime frame: From the date of intubation to the date of extubation without reintubation within 28 hours or date of death from any cause, whichever occurs first, assessed up to 30 days.
    • RemovedIntensive care unit (ICU) length of stay (LOS)Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.
    • RemovedHospital length of stay (LOS)Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
    • RemovedMortalityTime frame: At intensive care unit (ICU) discharge
    • RemovedMortalityTime frame: Up to 30 days
    • RemovedClinician adherence to initially assigned spontaneous breathing trial (SBT) modeTime frame: Up to 30 days
    • RemovedVentilator associated complicationsTime frame: From the date of intubation to the date of extubation without reintubation in 48 hours or death from any cause, whichever occurs first, assessed up to 30 days.
    • DescriptionTime to successful extubation: how it is measured was reworded
    • Addedother outcomeVentilator-free daysTime frame: From study enrollment to 28 days after enrollment
    • Addedother outcomeICU free days, censored at day 28Time frame: From study enrollment to 28 days after enrollment
    • Addedother outcomeHospital free daysTime frame: From study enrollment to 28 days after enrollment
    • Addedother outcomeSpontaneous breathing trial (SBT) resultsTime frame: Up to 30 days from study enrollment or until hospital discharge, whichever occurs first
    • Addedother outcomeReintubationTime frame: Within 48 hours after extubation
    • Addedother outcomeReintubationTime frame: Within 7 days after extubation
    • Addedother outcomeUse of noninvasive respiratory supportTime frame: Within 48 hours of extubation
    • Addedother outcomeTotal duration of mechanical ventilationTime frame: From the date of intubation to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
    • Addedother outcomeIntensive care unit (ICU) length of stay (LOS)Time frame: From the date of ICU admission to the date of ICU discharge, assessed up to 30 days.
    • Addedother outcomeHospital length of stay (LOS)Time frame: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
    • Addedother outcomeMortalityTime frame: At ICU discharge, censored at 28 days
    • Addedother outcomeClinician adherence to initially assigned spontaneous breathing trial (SBT) modeTime frame: Up to 30 days
    • Addedother outcomeSafety Events During SBTTime frame: From study enrollment to the date of extubation or death from any cause, whichever occurs first, assessed up to 30 days
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07005505
Responsible party
Jie Li (Professor, Rush University Medical Center) — Principal investigator
First posted
Jun 5, 2025
Start date
Jun 1, 2025
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Jie Li, PhD
Contact
Jie_Li@rush.edu
312-563-4643
Lauren Harnois, MSc
Contact
Lauren_J_Harnois@rush.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion